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these oscillations occur, but a direct experimental evidence for this
hypothesis is still missing.
We expressed and purified both proteins and developed a simpli-
fied in vitro system that enables us to test the assumptions and
predictions made by the theory.
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Error in template-based protein tertiary structure modeling is
unavoidable, but is not explicitly shown in most current prediction
algorithms. The error estimation in structure prediction provides
crucial information for experimental biologists who use predicted
models for design and interpretation of experiments. Here we
propose a method to estimate errors in predicted structures based
on the stability of the optimal alignment compared with a set of
suboptimal alignments. The stability of the optimal alignment is
numerated by an index named the SuboPtimal Alignment Diversity
(SPAD). SPAD is shown to have good correlation to actual predic-
tion errors, both alignment shift errors and the root mean square
deviation (RMSD) of predictedmodels to the native structures. This
discovered correlation can be described by a linear regression
function. Using this function, we have predicted the error of our
CASP7 structure predictions by SPAD and the result matches the
actual error well on the whole structure as well as at specific
residues. We have compared SPAD with several other prediction
quality measures such as the sequence identity between a target
sequence and a template sequence, the statistical distant dependent
atomic contact potential (DOPE), PRSS Z-score and the residue
conservation, the gap ratio and the mutation score in the profile.
Generally, SPAD is shown to have better correlation to actual
prediction error, which means it is one of the best error predictors
among these measures.
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The structural features of helical transmembrane proteins, such as
helical kinks, bends, tilts, and rotational orientations are important
in modulation of their function. These structural features modulate
the activation dynamics of membrane proteins. In particular, the
helical kinks caused by breaking of the backbone hydrogen bonds
lead to hinge bending flexibility in these helices. Biophysical
measurements such as spin labeling and EPR experiments and
computational simulations have shown the flexibility of helical
motion modulated by hinge bending region. Prolines and vestigial
prolines in the structure predominantly cause the helical kinks. It is
possible to have multiple helical kinks in one helix in the TM
proteins and this could contribute to achieving functional diversity
for a given structural topology. There are several other residues
besides prolines that are also known to cause kinks because of the
hydrogen bond between the side chains and the main chain of the
helix at residues like Ser, Thr, Asn, Gln.
In this study, we have used the crystal structures of all helical
membrane proteins (about 390 helices of length 19 to 35 residues
fromMPtopo database) to analyze the position and the extent of the
helical kinks in transmembrane proteins. We found that most of the
helical kinks are present at prolines or at vestigial prolines. However
there are kinks present at other residues such as Gly, Met, Ser, Thr,
and Cys. These results will be presented. We have also performed
molecular dynamics simulations, starting from a canonical helix for
the 390 TM helices. MD simulation results show that we can
reproduce about 80% of the proline kinks, only 56% of the vesitigal
proline kinks and 37% of the non-proline helical kinks.
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Activated Human Factor VIIIa is a 1424 residue length five-domain
blood coagulation protein cofactor that is critical for activation of
factor X by IXa in the intrinsic pathway. Despite its central role in
blood clotting, a full structure of FVIIIa is not known. In our efforts
to provide specific details of protein-protein interactions among
VIIIa, IXa and FX,we developed an all-atombased structuralmodel
for VIIIa based on its structural homology with recently reported
partial structure of bovine Va (1SDD) and ceruloplasmin (1KCW).
The homology model of A1A2 (A1- P740) heavy chain and A3-C1-
C2 (E1675-Y2332) of light-chain is further refined by explicit water
based MD simulations using AMBER FF99SB force-field. The
dynamic refinement of ~240,000 atom system (comprising of 1400
AA residues, protein bound copper and calcium ions together with
counter ions and PBC waters) for over a total period of 80 nano-
seconds yielded a stable assembly of fVIIIa structure whose details
provide a new look at the exisiting hypothesis of light-chain
interactions with membrane surface. We present a structure-func-
tion correlation of known genetic mutations and site-specific mu-
tagenesis data with our dynamic solution structure of FVIIIa.
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Fourier transform infrared (FTIR) spectroscopy opens a new field of
medical research, as it causes no damage to the constituents of the
cells or tissues. The amide I region (1700–1600 cm1) is commonly
used for the analysis of secondary structure of proteins in FTIR
spectra. In this particular spectral region, different protein confor-
mations result in different discrete bands, which are usually broad
and consequently overlapping. Neural networks have proven to be
an alternative powerful tool for the analysis of protein structure from
FTIR spectra [1]. In this work, neural networkswere initially trained
using a data set containing FTIR spectra of 18water soluble proteins
recorded in water whose secondary structures were known from X-
ray crystallographic analysis. The details of the training and testing
algorithm can be found in reference [1]. Here we applied this
technique to study the secondary structural changes of proteins in
rat brain tissues and homogenate membranes. The effect of antioxi-
dant administration such as lipoic acid [2] and the effect of epilepsy
on rat brain tissue and homogenate proteins, respectively were
reported. Lipoic acid treatment revealed an unaltered protein sec-
ondary structure suggesting that lipoic acid is non-toxic and thus
support the usage of lipoic acid as an antioxidant supplement.
However epilepsy caused a significant decrease in beta sheet
structure.
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Non-additivity of component free energies is a fundamental stum-
bling block on the path to a bottom-up understanding of biomole-
cules in terms of a free energy decomposition scheme [1]. Whereas
component enthalpies add, the corresponding conformational en-
tropies add only over independent degrees of freedom. Previously,
we constructed a Distance Constraint Model (DCM) to resolve the
problem of finding the total conformational entropy by summing
over only the strongest subset of independent components [2]. For
the alpha-helix to coil transition, an efficient transfer matrix method
was developed, and employed to describe multiple length homoge-
nous peptides in different solvents simultaneously, and without
introducing an ad hoc nucleation parameter [2]. This method was
then extended to nonhomogenous peptides [3] consisting of only
hydrophobic and polar type residues. However, there are twenty
naturally occurring amino acids in proteins (or peptides) with
diverse properties. Here, we begin to parameterize all the amino
acids in away consistent with the experimental data described in the
comprehensive review by Pace and Scholtz [4]. For numerical
determination of DCM parameters, experimental specific heat data
on four short peptides [5] involving six different amino acids {Y,A,
E,R,V,G} were successfully fitted simultaneously, and, these results
lend themselves to determination of the sought helix propensities for
each of these residues.
This work is supported by in part by Cal State, Channel Island
(GGW) and NIH R01 GM073082-01A1 (DJJ).
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Structure-based Drug Design
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The epidermal growth factor receptor (EGFR) is aberrantly activat-
ed in a variety of epithelial cancers and has been the focus of much
interest as a therapeutic target in anti-cancer therapy. Here we
characterize the inhibition of EGFR dimerization and activation
by an antibody drug that is currently in phase I/II clinical trials. The
progress of our structural and biochemical studies is presented. We
compare our results with those known for the antibody cetuximab/
Erbitux, which is FDA approved for colorectal as well as head and
neck cancer since 2004. Both antibodies bind to domain III of the
receptor, but show different inhibitionmechanisms. The similarities
and differences of the two antibodies have important implications
for the development of new therapeutic approaches of EGFR
targeting.
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Peptidoglycan Recognition Protein (PGRP) is a soluble, conserved
pattern recognition protein of vertebrates and invertebrates that
binds to peptidoglycans (PGNs). PGNs form a group of conserved
microbial motifs (Pathogen - associated molecular patterns-
PAMPs) that are unique products of microbial metabolism not
produced by the host. PGNs are located on the surface of virtually
all bacteria and fungi and as such, constitute excellent targets to
recognition by PGRPs. We have isolated a 20 kDa PGRP from
cameline mammary secretions. It has been crystallized in the space
group I222 with cell dimensions, a = 89.9A

, b = 102.5 A

, c = 164.2 A

having 32 molecules in the unit cell. The structure reveals the
presence of two crystallographically independent dimers unlike
human PGRP, which is a monomer. PGN binding groove is located
in the domain close to C-terminus. Themolecular structure contains
a central b-sheet composed of five b-strands, four parallel and one
(b5) antiparallel and three a-helices. PGN binding site resides in a
long cleft whosewalls are formed by helix a1 and five loops b3 - a1,
a1- b4, b5- b6, b6 - a2 , b7 - a3. The second site is located on the
opposite side of the proteins to the PGN-binding site, which
apparently accommodates host effector or signaling molecules. It
is formed by variable PGRP-specific segment and helix a2. Dis-
accaride is observed in the Ligand binding cleft and interacts with
residues such as Glu 52, Asn 55 and Thr 38 of the A molecule.
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The role of cyclooxygenase2 (COX2) enzyme in cancer promotion
has been discovered almost a decade back. But the novelmechanism
by which lipoxygenase (LOX) enzyme and its products are co-
promoting the COX2 in cancer cell proliferation is now raising a
new question. Will the dual inhibition of COX2 and LOX enzymes
block the cancerous proliferation of cells and if so to what extent?
Preliminary studies done on this novel mechanism of cancer pre-
vention by inhibiting COX2/5LOX have shown excellent positive
results.
Keeping this in mind, we have used the available X-ray crystal
structures of the complexes of COX2 and LOX with the known
inhibitors to carry out a structure-based, rational, molecular model-
ing approach to design a small peptide inhibitor, which is potent for
both COX and LOX. Since the crystal structure of 5LOX is not
known, and since the active sites of human 5LOX and mammalian
15LOX are highly similar, the crystal structure of rabbit 15LOX
enzyme has been used. Docking studies using Discovery Studio 1.7
(Accelrys Software Inc) indicate that the designed peptide inhibits
both 15LOXandCOX2with potency in the nanomolar range, which
is about 1000 timesmore than the known dual LOX/COX inhibitors.
Furthermore, this designed inhibitor also blocks the COX1 enzyme
so that the unwanted cardiovascular side effects of COX2 selective
inhibitors are avoided. Thus, the designed small peptide inhibitor is
a novel lead compound for the design of a new class of anti-cancer
drugs.
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